PharmEasy is staring at hard times
The online drugs and medical services startup made some costly acquisitions in a bid to pull off an IPO at a high valuation. That plan may be coming unstuck.
Subscribe to read this story
We publish over 500 original, detailed stories every year on startups, corporates, stock markets and economic current affairs.
$99 for one year
Not ready to subscribe? Sign up for a free account
We value our free readers. Read 100+ stories every year.
More in Business
You may also like
Peak XV Partners should win the record outcome test with Pine Labs
Finally, this question will be answered. Who has returned the most amount of capital on any venture investment in India in the last two decades?
Why is Swiggy catching flak for its latest quick-delivery promise?
The food and grocery delivery company’s idea of providing prescription drugs in 10 minutes is facing resistance from traditional pharma players.
Can Naveen Tahilyani fix Tata Digital’s rot?
The flop show of the super app Tata Neu isn’t the biggest problem for Tata Sons chairman N Chandrasekaran. The new CEO he has now picked has more fundamental issues to fix.